NCT06171685

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Multiple Myeloma Research Consortium · Network
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.

Conditions

• Relapse Multiple Myeloma
• Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Teclistamab Monotherapy	standard of care
DRUG	Teclistamab	investigational doses compared to SOC

Timeline

• Start date: 2024-11-17
• Primary completion: 2029-07-31
• Completion: 2030-07-31
• First posted: 2023-12-15
• Last updated: 2025-07-15

Locations

13 sites across 1 country: United States

Regulatory

• FDA-regulated drug study